Patent Antitrust

Patent rights grant a limited, government-approved monopoly — the right to exclude others from making, using, or selling the patented invention for a term. Antitrust law (Sherman Act § 1, § 2; Clayton Act § 7) prohibits agreements that restrain trade and unilateral conduct that monopolizes markets. These two regimes coexist, and courts have developed specific doctrines governing when patent-related conduct crosses into antitrust violation: THE CORE TENSION: a valid patent legitimately excludes competitors — that is its design; a patent holder may charge high royalties and refuse licenses without antitrust liability in most cases; WHEN PATENT CONDUCT BECOMES ANTITRUST: (1) WALKER PROCESS: obtaining a patent by FRAUD on the USPTO and then ENFORCING it to monopolize a market — antitrust liability; (2) SHAM LITIGATION: filing patent infringement suits without a genuine belief in their merit, to harm a competitor — antitrust liability; (3) REVERSE PAYMENT SETTLEMENTS (pay-for-delay): brand-name drug company pays generic to delay market entry, where the payment exceeds the value of avoided litigation — presumptively anti-competitive (FTC v. Actavis, S.Ct. 2013); (4) FRAND ABUSE: a standard-essential patent holder who committed to FRAND licensing and then seeks injunctions or excessive royalties — potential antitrust liability; (5) PATENT POOLS: a legitimate efficiency-enhancing arrangement, but pools that foreclose competition or include non-essential patents may violate § 1; (6) TYING: conditioning a patent license on the licensee purchasing unpatented products — illegal tying under § 1 (with market power) if the tied product is in a separate market.

Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., 382 U.S. 172 (S.Ct. 1965): a patent holder who (1) obtains a patent by FRAUD on the USPTO and (2) uses that fraudulently obtained patent to monopolize a relevant market violates Sherman Act § 2. ELEMENTS: (1) FRAUD ON THE USPTO: more than inequitable conduct — must meet the higher standard of common law fraud: knowing misrepresentation or omission of a MATERIAL fact; specific intent to deceive; the USPTO would NOT have granted the patent but for the misrepresentation; (2) PATENT ENFORCEMENT: the defendant must have used the fraudulent patent to assert market exclusivity or threaten/sue competitors; (3) RELEVANT MARKET: plaintiff must define a relevant product and geographic market in which the patented invention gives the defendant monopoly power; (4) MONOPOLY POWER: defendant must have or threaten to achieve monopoly power (typically > 70% market share) in the relevant market; (5) ANTITRUST INJURY: plaintiff must show injury from the anticompetitive conduct (competitive harm, not just the harm of losing a patent case); REMEDIES: treble damages (§ 4 Clayton Act) + attorney's fees; injunctive relief; FRCP 9(b) PLEADING: fraud must be pleaded with particularity — specify the who, what, when, where, how of the misrepresentation; vague inequitable conduct allegations insufficient for Walker Process; COMPARISON WITH INEQUITABLE CONDUCT: inequitable conduct → patent unenforceability; Walker Process → antitrust liability; Walker Process requires higher fraud standard (specific intent, materiality, but-for causation) + market power + antitrust injury.

Reverse payment settlements — also called pay-for-delay — arise in pharmaceutical patent litigation under the Hatch-Waxman Act. STRUCTURE: a brand-name pharmaceutical company holds a drug patent; a generic manufacturer files an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification challenging the patent's validity or non-infringement; the brand company sues for infringement (triggering a 30-month stay); instead of litigating to judgment, the parties settle — the generic agrees to delay market entry until a specified date, and the brand company pays the generic (directly or through 'reverse' payments: no-AG agreements, payment for services, licensing rights); WHY IT'S CALLED 'REVERSE': normal patent settlements pay the accused infringer to stop infringing; in pay-for-delay, the patent holder pays the alleged infringer to stay out of the market; FTC v. ACTAVIS (S.Ct. 2013): the Supreme Court held that reverse payment settlements are subject to antitrust scrutiny under the rule of reason (not per se legal and not per se illegal); large, unjustified reverse payments are suspect because: (1) they come from the brand company's patented profits; (2) they are not explained by the value of the services the generic provides; (3) they suggest the brand company fears the patent would be invalidated if litigated to judgment; SAFE HARBOR: settlements where the generic enters before patent expiry without a cash payment remain generally lawful; non-monetary reverse payments (no-AG agreements, product agreements) are also subject to Actavis analysis after FTC scrutiny; FTC ENFORCEMENT: FTC actively challenges large reverse payment settlements; annual settlements reviewed by FTC under statutory filing requirement.

When a patent is incorporated into a technical standard (by an SSO like IEEE, ETSI, 3GPP), the patent holder typically commits to license on FRAND (fair, reasonable, and non-discriminatory) terms. ANTITRUST DIMENSIONS: (1) HOLD-UP THEORY: a standard-essential patent (SEP) holder who makes a FRAND commitment but then demands supra-FRAND royalties or seeks injunctions against willing licensees may be exploiting market power created by the standardization process — potential § 2 violation; (2) REFUSAL TO LICENSE: in the US, refusers to license are generally not antitrust violations (Trinko); but a FRAND commitment creates a CONTRACT obligation to license, turning refusal into breach of contract rather than just an antitrust issue; EU antitrust is more aggressive — Huawei v. ZTE (CJEU 2015) framework for when seeking an injunction by an SEP holder constitutes an abuse of dominant position; (3) EXCLUSION ORDER RISK AT ITC: the Presidential Review Policy (2013 Obama administration) limited ITC exclusion orders for FRAND-committed SEPs against willing licensees; (4) ROYALTY STACKING: when many SEPs cover a standard, the aggregate FRAND rates may be excessive; courts consider portfolio licensing and FRAND rate-setting; (5) NON-DISCRIMINATION: FRAND's 'non-discriminatory' prong prohibits charging competitors higher rates than non-competitors for the same technology — a distinct antitrust concern from the 'reasonable' prong; US CASE LAW: Qualcomm Inc. v. FTC (9th Cir. 2020): reversed FTC's antitrust judgment against Qualcomm's SEP licensing practices (no duty to deal, FRAND breach alone ≠ Sherman Act § 2).

Patent pools are arrangements where multiple patent owners collectively license their patents to each other and/or to third parties. EFFICIENCY RATIONALE: pools reduce transaction costs (one license vs. many individual licenses); clear blocking patents (essential patents owned by different entities that together are necessary to practice a standard); reduce royalty stacking; LEGAL POOLS: (1) essential patents only — each patent in the pool is actually essential to practice the technology; no substitute; (2) licensing available to ALL on reasonable, non-discriminatory terms; (3) participants compete outside the pool on products and prices; (4) no output restrictions; (5) grantback provisions limited and FRAND-like; DOJ/FTC Business Review Letters: DOJ has issued favorable business review letters for pools covering MPEG-2, DVD technology, 3G wireless, RFID standards — all covering only essential patents with RAND licensing to all; ILLEGAL POOL ELEMENTS: (1) non-essential patents in the pool — competitors forced to cross-license non-substitutable IP, foreclosing competition; (2) price-fixing through pool royalty rates for competitive products made with the pooled patents; (3) market allocation — members agree to divide markets or customers; (4) exclusionary terms — pool refuses to license to certain competitors; (5) mandatory grantback of improvements (can chill innovation); STANDARD-SETTING POOLS: pools formed around industry standards (JPEG, HEVC, WiFi) receive favorable treatment when they include only essential patents and offer RAND terms universally; EU TTBER: EU Technology Transfer Block Exemption Regulation 316/2014 provides safe harbors for patent pools meeting specified criteria.